The Role of M6A Methylation in Targeted Therapy Resistance in Lung Cancer

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2024 Jul 15

PMID 39005690

Authors

Huange Xue

Yufei Ma

Kaiwen Guan

Yueyang Zhou

Yang Liu

Fei Cao

Xiaohong Kang

Affiliations

Soon will be listed here.

Abstract

Targeted therapies have greatly improved clinical outcomes for patients with lung cancer (LC), but acquired drug resistance and disease relapse inevitably occur. Increasingly, the role of epigenetic mechanisms in driving acquired drug resistance is appreciated. In particular, N6-methyladenosine (m6A), one of the most prevalent RNA modifications, has several roles regulating RNA stability, splicing, transcription, translation, and destruction. Numerous studies have demonstrated that m6A RNA methylation can modulate the growth and invasion of cancer cells as well as contribute to targeted therapy resistance in LC. In this study, we outline what is known regarding the function of m6A in the acquisition of targeted therapy resistance in LC.

Citing Articles

RNA Modification in Metabolism.

Liu Y, Sun Z, Gui D, Zhao Y, Xu Y MedComm (2020). 2025; 6(3):e70135.

PMID: 40066222 PMC: 11892166. DOI: 10.1002/mco2.70135.

References

Liu H, Lyu H, Jiang G, Chen D, Ruan S, Liu S . ALKBH5-Mediated m6A Demethylation of GLUT4 mRNA Promotes Glycolysis and Resistance to HER2-Targeted Therapy in Breast Cancer. Cancer Res. 2022; 82(21):3974-3986. DOI: 10.1158/0008-5472.CAN-22-0800. View

Kris M, Johnson B, Berry L, Kwiatkowski D, Iafrate A, Wistuba I . Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014; 311(19):1998-2006. PMC: 4163053. DOI: 10.1001/jama.2014.3741. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Lin Z, Li J, Zhang J, Feng W, Lu J, Ma X . Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer. Cancer Res. 2023; 83(13):2187-2207. DOI: 10.1158/0008-5472.CAN-22-3059. View

Linder B, Grozhik A, Olarerin-George A, Meydan C, Mason C, Jaffrey S . Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat Methods. 2015; 12(8):767-72. PMC: 4487409. DOI: 10.1038/nmeth.3453. View

Li K, Peng Z, Wang R, Li X, Du N, Liu D . Enhancement of TKI sensitivity in lung adenocarcinoma through m6A-dependent translational repression of Wnt signaling by circ-FBXW7. Mol Cancer. 2023; 22(1):103. PMC: 10314519. DOI: 10.1186/s12943-023-01811-0. View

Meyer K . DART-seq: an antibody-free method for global mA detection. Nat Methods. 2019; 16(12):1275-1280. PMC: 6884681. DOI: 10.1038/s41592-019-0570-0. View

Zhang Z, Chen L, Zhao Y, Yang C, Roundtree I, Zhang Z . Single-base mapping of mA by an antibody-independent method. Sci Adv. 2019; 5(7):eaax0250. PMC: 6609220. DOI: 10.1126/sciadv.aax0250. View

Wang F, Zhang J, Lin X, Yang L, Zhou Q, Mi X . METTL16 promotes translation and lung tumorigenesis by sequestering cytoplasmic eIF4E2. Cell Rep. 2023; 42(3):112150. DOI: 10.1016/j.celrep.2023.112150. View

10.

Beretta G, Cassinelli G, Pennati M, Zuco V, Gatti L . Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents. Eur J Med Chem. 2017; 142:271-289. DOI: 10.1016/j.ejmech.2017.07.062. View

11.

Wang M, Herbst R, Boshoff C . Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021; 27(8):1345-1356. DOI: 10.1038/s41591-021-01450-2. View

12.

Lee Y, Choe J, Park O, Kim Y . Molecular Mechanisms Driving mRNA Degradation by mA Modification. Trends Genet. 2020; 36(3):177-188. DOI: 10.1016/j.tig.2019.12.007. View

13.

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B . The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017; 7(3):339-348. PMC: 5651054. DOI: 10.15171/apb.2017.041. View

14.

Chen H, Jia B, Zhang Q, Zhang Y . Meclofenamic Acid Restores Gefinitib Sensitivity by Downregulating Breast Cancer Resistance Protein and Multidrug Resistance Protein 7 FTO/m6A-Demethylation/c-Myc in Non-Small Cell Lung Cancer. Front Oncol. 2022; 12:870636. PMC: 9069108. DOI: 10.3389/fonc.2022.870636. View

15.

Levantini E, Maroni G, Del Re M, Tenen D . EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol. 2022; 85:253-275. DOI: 10.1016/j.semcancer.2022.04.002. View

16.

Zhao S, Song P, Zhou G, Zhang D, Hu Y . METTL3 promotes the malignancy of non-small cell lung cancer by N6-methyladenosine modifying SFRP2. Cancer Gene Ther. 2023; 30(8):1094-1104. DOI: 10.1038/s41417-023-00614-1. View

17.

Ke S, Alemu E, Mertens C, Gantman E, Fak J, Mele A . A majority of m6A residues are in the last exons, allowing the potential for 3' UTR regulation. Genes Dev. 2015; 29(19):2037-53. PMC: 4604345. DOI: 10.1101/gad.269415.115. View

18.

Garcia-Campos M, Edelheit S, Toth U, Safra M, Shachar R, Viukov S . Deciphering the "mA Code" via Antibody-Independent Quantitative Profiling. Cell. 2019; 178(3):731-747.e16. DOI: 10.1016/j.cell.2019.06.013. View

19.

Xiao Y, Liu S, Ge R, Wu Y, He C, Chen M . Transcriptome-wide profiling and quantification of N-methyladenosine by enzyme-assisted adenosine deamination. Nat Biotechnol. 2023; 41(7):993-1003. PMC: 10625715. DOI: 10.1038/s41587-022-01587-6. View

20.

Yang Y, Qian Z, Feng M, Liao W, Wu Q, Wen F . Study on the prognosis, immune and drug resistance of m6A-related genes in lung cancer. BMC Bioinformatics. 2022; 23(1):437. PMC: 9583491. DOI: 10.1186/s12859-022-04984-5. View